 | Up a level |
2015
Walter, R. F. H., Mairinger, F. D., Ting, S., Vollbrecht, C., Mairinger, T., Theegarten, D., Christoph, D. C., Schmid, K. W. and Wohlschlaeger, J. (2015). MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53. Br. J. Cancer, 112 (5). S. 883 - 891. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827
Walter, R. F. H., Mairinger, F. D., Ting, S., Vollbrecht, C., Mairinger, T., Theegarten, D., Christoph, D. C., Schmid, K. W. and Wohlschlaeger, J. (2015). MDM2 is an important prognostic and predictive factor for platin-pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53. Br. J. Cancer, 112 (5). S. 883 - 891. LONDON: NATURE PUBLISHING GROUP. ISSN 1532-1827
2014
Nogova, L., Gardizi, M., Bos, M., Scheffler, M., Papachristou, I., Woempner, C., Heukamp, L., Schildhaus, H. -U., Fuhr, U., Sos, M., Eberhardt, W., Wiesweg, M., Schmid, K. W., Schuler, M., Thomas, R., Buettner, R. and Wolf, J. (2014). TRY: A phase II study to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small-cell lung cancer (NSCLC) with HER2 overexpression or amplification or mutation. Oncol. Res. Treat., 37. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262